$3.75 -0.02 (-0.53%)
12/3/2009 4:00 PM

Arena Pharmaceuticals, Inc. (ARNA)

CAPS Rating: 3 out of 5

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Recs

0
Member Avatar kevin76013 (37.56) Submitted: 6/20/2008 12:28:50 AM : Outperform Start Price: $4.68 ARNA Score: -5.53

Biotech stock, hauled out and shot to near cash value. Principal drug is anti-obesity Locaserin, in Phase 3 trials ending March 09. Making a good deal with a major biotech, let alone skating through to FDA approval would change the perpetual bearish sentiment here.

Report this Post 0 Comments

Featured Broker Partners